These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 25299917)

  • 61. China spurs pharma innovation.
    Hughes B
    Nat Rev Drug Discov; 2010 Aug; 9(8):581-2. PubMed ID: 20671751
    [No Abstract]   [Full Text] [Related]  

  • 62. Mads Krogsgaard Thomsen. Interview by Asher Mullard.
    Thomsen MK
    Nat Rev Drug Discov; 2014 Feb; 13(2):96-7. PubMed ID: 24481301
    [No Abstract]   [Full Text] [Related]  

  • 63. The biopharmaceutical industry in China: history and future perspectives.
    Gao K; Wang J
    Front Med; 2012 Jun; 6(2):101-11. PubMed ID: 22544299
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Can next-generation antibodies offset biosimilar competition?
    Mullard A
    Nat Rev Drug Discov; 2012 Jun; 11(6):426-8. PubMed ID: 22653202
    [No Abstract]   [Full Text] [Related]  

  • 65. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
    Thill M
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Assessment of biotechnology drugs: what are the issues?
    van Rijkom J; Leufkens H; Crommelin D; Rutten F; Broekmans A
    Health Policy; 1999 Jun; 47(3):255-74. PubMed ID: 10538922
    [TBL] [Abstract][Full Text] [Related]  

  • 67. What's fueling the biotech engine-2007.
    Aggarwal S
    Nat Biotechnol; 2008 Nov; 26(11):1227-33. PubMed ID: 18997759
    [No Abstract]   [Full Text] [Related]  

  • 68. Biotech industry tries to recover from 2-year lull.
    Brower V
    J Natl Cancer Inst; 2003 Mar; 95(5):348-9. PubMed ID: 12618496
    [No Abstract]   [Full Text] [Related]  

  • 69. Examining the Causes and Consequences of Increasing Insulin Costs With Prospective Interventions.
    Dawkins M; Menon T; Myers AK
    Am J Ther; 2020; 27(1):e115-e120. PubMed ID: 31703009
    [No Abstract]   [Full Text] [Related]  

  • 70. Growing pains for biopharmaceuticals.
    Ashton G
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract]   [Full Text] [Related]  

  • 71. AchemAsia 2007 announcement: China's biotechnology industry on the upswing.
    Biotechnol J; 2007 Mar; 2(3):288-90. PubMed ID: 17354215
    [No Abstract]   [Full Text] [Related]  

  • 72. The socialite scientist.
    Serwer A
    Fortune; 2002 Apr; 145(8):152-4, 158, 160 passim. PubMed ID: 11961885
    [No Abstract]   [Full Text] [Related]  

  • 73. The commercial development of gene therapy in Europe and the USA.
    Martin PA; Thomas SM
    Hum Gene Ther; 1998 Jan; 9(1):87-114. PubMed ID: 9458246
    [No Abstract]   [Full Text] [Related]  

  • 74. Antisoma-Roche deal--a new kind of buyout?
    Mitchell P
    Nat Biotechnol; 2003 Jan; 21(1):3. PubMed ID: 12511894
    [No Abstract]   [Full Text] [Related]  

  • 75. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dissecting monoclonal antibody mega-deals.
    Villiger R; Bogdan B
    MAbs; 2009; 1(2):172-8. PubMed ID: 20061828
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Innovator Organizations in New Drug Development: Assessing the Sustainability of the Biopharmaceutical Industry.
    Kinch MS; Moore R
    Cell Chem Biol; 2016 Jun; 23(6):644-53. PubMed ID: 27341432
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmaceutical biotechnology products approved within the European Union.
    Walsh G
    Eur J Pharm Biopharm; 2003 Jan; 55(1):3-10. PubMed ID: 12551698
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pipelines turn to biotech.
    Lawrence S
    Nat Biotechnol; 2007 Dec; 25(12):1342. PubMed ID: 18066015
    [No Abstract]   [Full Text] [Related]  

  • 80. Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development.
    Calvo B; Zuñiga L
    Curr Med Chem; 2012; 19(26):4445-50. PubMed ID: 22978327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.